Cargando…

Development of Transdermal Oleogel Containing Olmesartan Medoxomil: Statistical Optimization and Pharmacological Evaluation

Olmesartan medoxomil (OLM) is a first-line antihypertensive drug with low oral bioavailability (28.6%). This study aimed to develop oleogel formulations to decrease OLM side effects and boost its therapeutic efficacy and bioavailability. OLM oleogel formulations were composed of Tween 20, Aerosil 20...

Descripción completa

Detalles Bibliográficos
Autores principales:	El-Dahmy, Rania Moataz, Elsayed, Ibrahim, Hussein, Jihan, Althubiti, Mohammad, Almaimani, Riyad A., El-Readi, Mahmoud Zaki, Elbaset, Marawan A., Ibrahim, Bassant M. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146305/ https://www.ncbi.nlm.nih.gov/pubmed/37111569 http://dx.doi.org/10.3390/pharmaceutics15041083

Ejemplares similares

Use of transethosomes for enhancing the transdermal delivery of olmesartan medoxomil: in vitro, ex vivo, and in vivo evaluation
por: Albash, Rofida, et al.
Publicado: (2019)

Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment
por: Albash, Rofida, et al.
Publicado: (2019)

Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
por: Greathouse, Mark
Publicado: (2006)

Spectrophotometric Estimation of Olmesartan Medoxomil and Hydrochlorothiazide in Tablet
por: Rote, A. R., et al.
Publicado: (2010)

Olmesartan medoxomil for the treatment of hypertension in children and adolescents
por: Tocci, Giuliano, et al.
Publicado: (2011)

Formulation and Evaluation of Liquisolid Compacts for Olmesartan Medoxomil
por: Prajapati, Shailesh T., et al.
Publicado: (2013)

Olmesartan medoxomil: Allergic reaction: case report
Publicado: (2022)

Overexpression of Inducible Nitric Oxide Synthase in Allergic and Nonallergic Nasal Polyp
por: Sadek, Ahmed Adel, et al.
Publicado: (2019)

Olmesartan medoxomil: current status of its use in monotherapy
por: Brunner, Hans R
Publicado: (2006)

Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement
por: Thakkar, Hetal Paresh, et al.
Publicado: (2011)

Small bowel enteropathy associated with olmesartan medoxomil treatment
por: Galanopoulos, Michail, et al.
Publicado: (2017)

Olmesartan-medoxomil: Sprue-like enteropathy: case report
Publicado: (2021)

Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
por: Punzi, Henry A
Publicado: (2011)

Linear mixed‐effects model of QTc prolongation for olmesartan medoxomil
por: Song, SaeHeum, et al.
Publicado: (2016)

Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil
por: Ferrario, Carlos
Publicado: (2009)

Simultaneous Estimation of Amlodipine Besilate and Olmesartan Medoxomil in Pharmaceutical Dosage Form
por: Wankhede, S. B., et al.
Publicado: (2009)

Human Carboxymethylenebutenolidase as a Bioactivating Hydrolase of Olmesartan Medoxomil in Liver and Intestine
por: Ishizuka, Tomoko, et al.
Publicado: (2010)

Design of Olmesartan Medoxomil-Loaded Nanosponges for Hypertension and Lung Cancer Treatments
por: Almutairy, Bjad K., et al.
Publicado: (2021)

Exploring the Effectiveness and Safety of Azilsartan-Medoxomil/Chlorthalidone Versus Olmesartan-Medoxomil/Hydrochlorothiazide in Hypertensive Patients: A Meta-Analysis
por: Kumar, Lakshya, et al.
Publicado: (2023)

Development of a novel 96-microwell assay with high throughput for determination of olmesartan medoxomil in its tablets
por: Darwish, Ibrahim A, et al.
Publicado: (2012)

Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil
por: Mason, R Preston
Publicado: (2011)

Derivative and Q-analysis Spectrophotometric Methods for Estimation of Hydrochlorothiazide and Olmesartan Medoxomil in Tablets
por: Bhusari, K. P., et al.
Publicado: (2009)

Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension
por: Chrysant, S G, et al.
Publicado: (2010)

Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial
por: Sohn, Il Suk, et al.
Publicado: (2015)

Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial
por: Sohn, Il Suk, et al.
Publicado: (2016)

Multiple Molecular Mechanisms to Overcome Multidrug Resistance in Cancer by Natural Secondary Metabolites
por: El-Readi, Mahmoud Zaki, et al.
Publicado: (2021)

Antioxidative and Anti-Inflammatory Protective Effects of Fucoxanthin against Paracetamol-Induced Hepatotoxicity in Rats
por: Koshak, Maimonah Fuad, et al.
Publicado: (2023)

A Competent and Commercially Viable Process for the Synthesis of the Anti-Hypertensive Drug Olmesartan Medoxomil
por: Hanumantha Rao, Bommena, et al.
Publicado: (2015)

Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension: Preparation by combinative technology
por: Attari, Zenab, et al.
Publicado: (2016)

Preparation and Characterization of Self-Microemulsifying Drug Delivery System of Olmesartan Medoxomil for Bioavailability Improvement
por: Prajapati, Shailesh T., et al.
Publicado: (2013)

A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval
por: Mendell, Jeanne, et al.
Publicado: (2015)

Hydrochlorothiazide/ibuprofen/olmesartan medoxomil: Drug misuse and acute tubular injury: case report
Publicado: (2021)

Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System
por: Elsayed, Ibrahim, et al.
Publicado: (2019)

Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals
por: Basile, Jan
Publicado: (2010)

Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study
por: Barrios, Vivencio, et al.
Publicado: (2009)

RP-LC and HPTLC Methods for the Determination of Olmesartan Medoxomil and Hydrochlorothiazide in Combined Tablet Dosage Forms
por: Bari, P. D., et al.
Publicado: (2009)

Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice
por: Zhu, Ye, et al.
Publicado: (2019)

Formulation and Development of Oral Fast-Dissolving Films Loaded with Nanosuspension to Augment Paroxetine Bioavailability: In Vitro Characterization, Ex Vivo Permeation, and Pharmacokinetic Evaluation in Healthy Human Volunteers
por: Elshafeey, Ahmed Hassen, et al.
Publicado: (2021)

A novel oral medicated jelly for enhancement of etilefrine hydrochloride bioavailability: In vitro characterization and pharmacokinetic evaluation in healthy human volunteers
por: Hassen Elshafeey, Ahmed, et al.
Publicado: (2022)

Safety and tolerability of fixed antihypertensive combinations in blood pressure control: focus on olmesartan medoxomil and amlodipine combination
por: Uddin, Ijlal, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ou77fblf7rbsfv9j93sk2s045d